AX-2026-041411 · GHRP-6 · QYB lot QYB-2602-X4422

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 15 min gradient, 214 nm	99.18	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.82	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — des-Lys (−128 Da)	0.31	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	92.88	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	92.12	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	2.26	mg	2 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	2.082	mg	2 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	104.1	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	1.95	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.80	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.37	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	Off-white lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear after 90 s gentle swirling, no particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	5.14	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 15 min gradient	4.46	min	4.56 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	0.97	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	56,037	—	≥ 20,000	PASS
Resolution to nearest impurity	vs [D-Trp]-epimer	0.78	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 15 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 56,037, and skew follows the reported asymmetry factor of 0.97. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.31 % impurity against a 99.18 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	GHRP-6 — main peak	4.46	4,820,455	99.18	—
2	des-Lys (−128 Da)	4.35	15,067	0.31	-128.095
3	bis-oxidised Trp (+32 Da)	4.17	12,637	0.26	+31.990
4	[D-Trp]-epimer	4.40	6,804	0.14	0.000
5	oxidised Trp (+16 Da)	4.29	5,346	0.11	+15.995
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	1.95
Counter-ion (acetate)	ion chromatography	4.80
Residual solvent + inorganic residue	estimated	0.37
Total peptide content	by difference	92.88
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.62	99.18	divergence +0.29 pp vs batch median
Total impurities (% area)	not stated	0.82
Largest single impurity (% area)	not stated	0.31
Water (%)	0.6	1.95
Counter-ion (%)	not stated	4.80
Peptide content (%w/w)	not stated	92.88
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → third-party forwarder (18 d) → laboratory (courier, cold pack, 5 d) → assay.
Assay date: 16 Jan 2026
Submitted to the index: 31 Jan 2026
Laboratory: Kestrel Bioanalytical, Melbourne, Australia
Method basis: 15 min gradient · unit-resolution MS
Verification status: PURITY ONLY

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 2

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

label_claim31 Jan 2026

A retail vial is also a test of the label. Declared claim 2 mg against what the gravimetry recovers is a question only a purchased vial can answer honestly.

multiple_compare31 Jan 2026

Restricting every supplier comparison to buyer-sourced records is the sensitivity analysis the scorecards publish. On the current dataset it changes no ordering that was not already inside measurement noise.

Section 7

Related records

Same batch — lot QYB-2602-X4422 n=6

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041406	QYB-2602-X4422	Janoshik	2026-Q1	99.32	1.68	—	Buyer-sourced	0	PASS
AX-2026-041407	QYB-2602-X4422	Janoshik	2026-Q1	99.48	1.80	107.2	Buyer-sourced	0	PASS
AX-2026-041408	QYB-2602-X4422	Medutest	2026-Q1	99.18	1.36	107.4	Buyer-sourced	1	MARGINAL
AX-2026-041409	QYB-2602-X4422	Nordanalyt	2026-Q1	99.34	1.61	—	Buyer-sourced	0	PASS
AX-2026-041410	QYB-2602-X4422	Nordanalyt	2026-Q1	99.39	1.99	—	Buyer-sourced	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent GHRP-6 records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042012	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.37	5.90	88.8	Laboratory-retained	1	MARGINAL
AX-2026-042528	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	98.69	1.87	95.8	Buyer-sourced	0	FAIL
AX-2026-042015	AMB	AMB-2603-S5667	Janoshik	2026-Q3	99.54	6.44	97.1	Buyer-sourced	0	PASS
AX-2026-042526	HJ	HJ-2603-R5329	Medutest	2026-Q3	99.37	3.06	—	Laboratory-retained	0	PASS
AX-2026-042527	HJ	HJ-2603-R5329	VendorInvestigate	2026-Q3	99.21	2.77	93.2	Buyer-sourced	0	PASS
AX-2026-042525	HJ	HJ-2603-R5329	Janoshik	2026-Q3	99.52	3.24	92.0	Buyer-sourced	0	PASS
AX-2026-042013	AMB	AMB-2603-S5667	Kestrel	2026-Q3	99.93	5.75	—	Buyer-sourced	0	PASS
AX-2026-042017	AMB	AMB-2603-S5667	Medutest	2026-Q3	99.76	6.42	97.4	Buyer-sourced	0	PASS

Other recent QYB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041471	PT-141 (Bremelanotide)	QYB-2607-L4875	Janoshik	2026-Q3	99.72	3.75	101.7	Buyer-sourced	0	PASS
AX-2026-041377	Ipamorelin	QYB-2605-H3558	Nordanalyt	2026-Q3	99.93	4.35	—	Buyer-sourced	0	PASS
AX-2026-041427	Retatrutide	QYB-2604-B4920	PeptideMeter	2026-Q3	97.93	2.45	101.7	Buyer-sourced	0	PASS
AX-2026-041428	Retatrutide	QYB-2604-B4920	Janoshik	2026-Q3	98.35	3.20	—	Laboratory-retained	0	PASS
AX-2026-041473	PT-141 (Bremelanotide)	QYB-2607-L4875	PeptideMeter	2026-Q3	99.58	3.74	94.4	Buyer-sourced	0	PASS
AX-2026-041472	PT-141 (Bremelanotide)	QYB-2607-L4875	PeptideMeter	2026-Q3	99.93	3.94	—	Buyer-sourced	0	PASS
AX-2026-041429	Retatrutide	QYB-2604-B4920	Medutest	2026-Q3	98.53	2.69	99.8	Buyer-sourced	1	MARGINAL
AX-2026-041431	Retatrutide	QYB-2604-B4920	Janoshik	2026-Q3	98.63	2.32	94.2	Buyer-sourced	0	PASS